Epicrispr Completes Enrollment and Dose Escalation in First-in-Human EPI-321 Trial for FSHD

Interim data demonstrated a favorable safety profile and early evidence of disease modification, including statistically significant increases in lean muscle volume and biomarker changes consistent with DUX4 suppression Additional clinical data expected to be presented at the World Muscle Society Annual Congress in September 2026 SAN FRANCISCO–(BUSINESS WIRE)–Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, … Read more